Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21052129 | 1.00 | PDE4B (0.44) | PDE4BNR1H2USP30EPHX1CTSK | |
| SCHEMBL21052130 | 1.00 | PDE4B (0.44) | PDE4BNR1H2USP30EPHX1CTSK | |
| SCHEMBL21092354 | 0.91 | PDE4B (0.38) | PDE4BNR1H2USP30EPHX1MAOA | |
| SCHEMBL3621440 | 0.90 | CTSK (0.36) | PDE4BUSP30CTSKCA1CA2 | |
| SCHEMBL18811768 | 0.84 | NR1H2 (0.47) | NR1H2EPHX1USP2SMN1; SMN2GPR119 | |
| SCHEMBL18811702 | 0.84 | NR1H2 (0.47) | NR1H2EPHX1USP2SMN1; SMN2GPR119 | |
| SCHEMBL2933886 | 0.84 | NR1H2 (0.47) | NR1H2EPHX1USP2SMN1; SMN2GPR119 | |
| SCHEMBL15805570 | 0.83 | PDE4B (0.47) | PDE4BNR1H2USP30EPHX1CTSK | |
| SCHEMBL20479586 | 0.82 | PDE4B (0.47) | PDE4BUSP30CTSKCA1CA2 | |
| SCHEMBL20479584 | 0.82 | PDE4B (0.47) | PDE4BUSP30CTSKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019111218-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2019-06-13 | — | — | WO | disclosed |
| EP-1978804-B1 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| US-7750034-B2 | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090270467-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270467-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | PDE4B 265/4885NR1H2 1466/4885USP30 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.